Vanguard Group Inc
- SEC CIK
- 0000102909
- Latest filing
- Jan 29, 2026
IKT holding history
Inhibikase Therapeutics, Inc. in every 13F filed by Vanguard Group Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
IKT overviewAll 13F holders of IKTFull Q4 2025 holdings
- Shares (Q4 2025)
- 4,558,604
- Value
- $9.35M
- % of portfolio
- <0.1%
- Quarters held
- 19
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2025 | 4,558,604 | $9.35M | <0.1% | +1,285,265+39.3% | Added | Holders |
| Q3 2025 | 3,273,339 | $5.30M | <0.1% | +48,969+1.5% | Added | Holders |
| Q2 2025 | 3,224,370 | $6.29M | <0.1% | +375,707+13.2% | Added | Holders |
| Q1 2025 | 2,848,663 | $6.24M | <0.1% | +10,018+0.4% | Added | Holders |
| Q4 2024 | 2,838,645 | $9.23M | <0.1% | +2,821,921+16,873.5% | Added | Holders |
| Q3 2024 | 16,724 | $21.7K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 16,724 | $20.2K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2024 | 16,724 | $36.1K | <0.1% | −65,321−79.6% | Reduced | Holders |
| Q4 2023 | 82,045 | $104.2K | <0.1% | −5,402−6.2% | Reduced | Holders |
| Q3 2023 | 87,447 | $121.6K | <0.1% | −863−1.0% | Reduced | Holders |
| Q2 2023 | 88,310 | $318.8K | <0.1% | 00.0% | UnchangedConverted for a 1-for-6 split | Holders |
| Q1 2023 | 530,276 | $348.7K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 530,276 | $265.1K | <0.1% | +1780.0% | Added | Holders |
| Q3 2022 | 530,098 | $482.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 530,098 | $394.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2022 | 530,098 | $785.0K | <0.1% | +51,394+10.7% | Added | Holders |
| Q4 2021 | 478,704 | $704.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2021 | 478,704 | $909.0K | <0.1% | +8,089+1.7% | Added | Holders |
| Q2 2021 | 470,615 | $1.32M | <0.1% | +470,615 | New | Holders |